文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

2022 年儿童家族性高胆固醇血症诊断与治疗指南。

Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022.

机构信息

Cardiovascular Center, Osaka Medical and Pharmaceutical University.

Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute.

出版信息

J Atheroscler Thromb. 2023 May 1;30(5):531-557. doi: 10.5551/jat.CR006. Epub 2023 Jan 20.


DOI:10.5551/jat.CR006
PMID:36682777
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10164603/
Abstract

As atherosclerosis begins in childhood, early diagnosis and treatment of familial hypercholesterolemia (FH) is considered necessary. The basic diagnosis of pediatric FH (under 15 years of age) is based on hyper-low-density lipoprotein (LDL) cholesterolemia and a family history of FH; however, in this guideline, to reduce overlooked cases, "probable FH" was established. Once diagnosed with FH or probable FH, efforts should be made to promptly provide lifestyle guidance, including diet. It is also important to conduct an intrafamilial survey, to identify family members with the same condition. If the level of LDL-C remains above 180 mg/dL, drug therapy should be considered at the age of 10. The first-line drug should be statin. Evaluation of atherosclerosis should be started using non-invasive techniques, such as ultrasound. The management target level is an LDL-C level of less than 140 mg/dL. If a homozygous FH is suspected, consult a specialist and determine the response to pharmacotherapy with evaluating atherosclerosis. If the response is inadequate, initiate lipoprotein apheresis as soon as possible.

摘要

由于动脉粥样硬化始于儿童期,因此人们认为有必要早期诊断和治疗家族性高胆固醇血症(FH)。儿科 FH(15 岁以下)的基本诊断基于极低密度脂蛋白(LDL)胆固醇升高和 FH 的家族史;但是,在本指南中,为了减少漏诊病例,“可能的 FH”被确立。一旦诊断为 FH 或可能的 FH,应努力及时提供生活方式指导,包括饮食。进行家庭内调查以确定具有相同情况的家庭成员也很重要。如果 LDL-C 水平仍高于 180mg/dL,则应在 10 岁时考虑药物治疗。一线药物应为他汀类药物。应使用超声等非侵入性技术开始评估动脉粥样硬化。管理目标水平是 LDL-C 水平低于 140mg/dL。如果怀疑为纯合子 FH,应咨询专家,并通过评估动脉粥样硬化来确定对药物治疗的反应。如果反应不足,应尽快开始脂蛋白吸附治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a2e/10164603/78b2b5862600/30_CR006_6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a2e/10164603/f73c5016f666/30_CR006_1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a2e/10164603/c2f2d1182b57/30_CR006_2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a2e/10164603/c05a419f0c56/30_CR006_3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a2e/10164603/fcb3747bac56/30_CR006_4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a2e/10164603/8ae1bb25d857/30_CR006_5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a2e/10164603/78b2b5862600/30_CR006_6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a2e/10164603/f73c5016f666/30_CR006_1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a2e/10164603/c2f2d1182b57/30_CR006_2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a2e/10164603/c05a419f0c56/30_CR006_3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a2e/10164603/fcb3747bac56/30_CR006_4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a2e/10164603/8ae1bb25d857/30_CR006_5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a2e/10164603/78b2b5862600/30_CR006_6.jpg

相似文献

[1]
Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022.

J Atheroscler Thromb. 2023-5-1

[2]
Familial Hypercholesterolemia

1993

[3]
Statins for children with familial hypercholesterolemia.

Cochrane Database Syst Rev. 2017-7-7

[4]
Statins for children with familial hypercholesterolemia.

Cochrane Database Syst Rev. 2014-7-23

[5]
Statins for children with familial hypercholesterolemia.

Cochrane Database Syst Rev. 2010-7-7

[6]
Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.

JAMA. 2016-8-9

[7]
Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.

Health Technol Assess. 2012

[8]
Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.

Health Technol Assess. 2000

[9]
Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia.

J Am Heart Assoc. 2016-7-6

[10]
Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries.

Lancet Child Adolesc Health. 2024-7

引用本文的文献

[1]
Pediatric Familial Hypercholesterolemia: Targeting Intestinal Absorption and Other Therapeutic Strategies.

Nutrients. 2025-7-18

[2]
Lifestyle Medicine Education and Pediatrics: Where We Are and Where We Need to Go.

Am J Lifestyle Med. 2025-7-20

[3]
Genetic Spectrum of Lithuanian Familial Hypercholesterolemia Patients.

J Cardiovasc Dev Dis. 2025-5-21

[4]
Diagnosis and Screening Strategies for Detection of Familial Hypercholesterolaemia in Children and Adolescents in Italy: A Survey from the LIPIGEN Paediatric Group.

Children (Basel). 2025-2-26

[5]
Familial hypercholesterolemia in patients with hypertension: the China H-type Hypertension Registry Study.

Lipids Health Dis. 2025-3-27

[6]
Impact of Genetic Testing and Sex Differences among Patients with Familial Hypercholesterolemia: The Hokuriku-plus Familial Hypercholesterolemia Registry Study.

J Atheroscler Thromb. 2025-7-1

[7]
The First Japanese Case of Familial Hypercholesterolemia Caused by an apolipoprotein E (APOE) p.Leu167del Mutation.

Intern Med. 2025-6-15

[8]
The Importance of Genetic Testing for Familial Hypercholesterolemia: A Pediatric Pilot Study.

Medicina (Kaunas). 2024-9-29

[9]
Assessment of Low-density Lipoprotein Cholesterol Levels and Non-invasive Vascular Health in School-aged Children: A Study in Ogasa District, Shizuoka Prefecture.

J Atheroscler Thromb. 2025-3-1

[10]
Characteristics, Physiopathology and Management of Dyslipidemias in Pregnancy: A Narrative Review.

Nutrients. 2024-9-1

本文引用的文献

[1]
Universal Screening for Familial Hypercholesterolemia in Children in Kagawa, Japan.

J Atheroscler Thromb. 2022-6-1

[2]
Genetic Analysis of Japanese Children Clinically Diagnosed with Familial Hypercholesterolemia.

J Atheroscler Thromb. 2022-5-1

[3]
Changes in Serum Cholesterol in Childhood and its Tracking to Adulthood.

J Atheroscler Thromb. 2022-1-1

[4]
The first Japanese cases of familial hypercholesterolemia due to a known pathogenic APOB gene variant, c.10580 G>A: p.(Arg3527Gln).

J Clin Lipidol. 2020

[5]
Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis.

Circulation. 2020-6-2

[6]
Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects.

J Am Coll Cardiol. 2020-5-26

[7]
A catalog of the pathogenic mutations of LDL receptor gene in Japanese familial hypercholesterolemia.

J Clin Lipidol. 2020

[8]
Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.

Atherosclerosis. 2019-11-15

[9]
Statins for children with familial hypercholesterolemia.

Cochrane Database Syst Rev. 2019-11-7

[10]
20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia.

N Engl J Med. 2019-10-17

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索